AIMed · Antimicrobial Integrated Methodologies for orthopaedic applications

Antimicrobial Integrated Methodologies for orthopaedic applications

AIMed has achieved its scientific and training goals, demonstrating that bio-inspired peptides, ion-doped ceramics and laser-engineered surfaces can prevent bacterial colonisation without antibiotics. The project lays the foundation for next-generation infection-resistant implants that will lower healthcare costs, reduce antibiotic dependence and improve patients’ quality of life. Context and relevance Implant-associated infections are a major complication in orthopaedic and trauma surgery. Despite strict sterilisation, bacterial adhesion and biofilm formation still cause implant failure, repeated operations and long hospital stays. These infections are increasingly difficult to treat due to antimicrobial resistance (AMR), a global health threat identified by the WHO and European Commission. Developing new antibiotics is costly and slow, while bacteria evolve resistance rapidly. Thus, antibiotic-free solutions for infection prevention are urgently needed. Post-surgical infections affect up to 5 % of orthopaedic procedures, with treatment costs exceeding €2 billion per year in Europe. AIMed’s contribution Orthopaedic and dental implants are vital for maintaining mobility and quality of life, particularly in an ageing population. Preventing infections directly supports EU priorities on sustainable healthcare and AMR reduction. AIMed addresses this by creating materials and surface technologies that prevent infection at the source. Project concept and objectives The AIMed (Antimicrobial Integrated Methodologies for Orthopaedic Applications) network united 12 beneficiaries and 7 partner organisations from academia and industry. It trained 15 PhD researchers (ESRs) in materials science, chemistry, biology and engineering. The project aimed to: 1. Design novel antimicrobial peptides (AMPs) inspired by human defensins and cathelicidins. 2. Functionalise metals, ceramics and polymers with AMPs or antibacterial ions (Ag, Cu, Zn). 3. Develop laser-patterned and 3D-printed materials with anti-biofilm properties. 4. Establish testing and regulatory frameworks for clinical translation. 5. Train ESRs with advanced scientific and transferable skills. Main results and conclusions Over 20 new AMPs were developed; two lead candidates (KR-12, B3AX2) showed broad antimicrobial activity and low toxicity. Functionalised materials achieved over 95 % bacterial inhibition and high biocompatibility. AIMed contributed to ISO TC 150 and ASTM F04 standards, completed all training events despite pandemic challenges, and built a sustainable European research network linking academia, healthcare and industry.

Data: CORDIS, © European Union